Výsledky vyhledávání - "Renata Sawtell"

Abstract CT184: Emerging evidence of activity of BLU-945 in patients with advanced EGFR-mutant NSCLC utilizing circulating tumor DNA (ctDNA) in the phase 1/2 SYMPHONY study

Autor: Elaine Shum, Yasir Elamin, Karen L. Reckamp, Zofia Piotrowska, Julia Rotow, Daniel S. Tan, Koichi Goto, Jagan Parepally, Faris Albayya, Melinda Louie-Gao, Renata Sawtell, Alena Zalutskaya, David Spigel

Publikováno v: Cancer Research. 82:CT184-CT184

Background: Despite recent advances in the treatment of EGFR-mutant (EGFRm) non-small cell lung cancer (NSCLC), most patients treated with third-generation (3G) EGFR tyrosine kinase inhibitors (TKIs), such as osimertinib, experience disease progressi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d9f3dd35390302c510c4e46746a36327
https://doi.org/10.1158/1538-7445.am2022-ct184

Zobrazit plný text záznamu

Abstract P230: A phase 1/2 study of BLU-945, a highly potent and selective inhibitor of epidermal growth factor receptor (EGFR) resistance mutations, in patients with EGFR-mutant non-small cell lung cancer (NSCLC)

Autor: David Spigel, Koichi Goto, D. Ross Camidge, Yasir Elamin, Adrianus J. de Langen, Natasha B. Leighl, Anna Minchom, Zofia Piotrowska, David Planchard, Karen Reckamp, Faris Albayya, Jennifer Green, Sean Kim, Melinda Louie-Gao, Renata Sawtell, Alena Zalutskaya, Byoung Chul Co

Publikováno v: Molecular Cancer Therapeutics. 20:P230-P230

BACKGROUND Activating EGFR mutations such as exon 19 deletion (ex19del) and L858R mutations, exon 19 insertions (ex19ins), and point mutations L861Q, G719X, and S768I are oncogenic drivers in lung adenocarcinoma, the most common NSCLC subtype. Althou

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60f5be95bc20799ec26fcc0672889da9
https://doi.org/10.1158/1535-7163.targ-21-p230

Zobrazit plný text záznamu

Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis

Autor: John E. Moran, Gary R. Albert, Lyne Gagnon, Nasreen Khalil, Martin Kolb, Frank Cesari, Joseph M. Parker, Christopher J. Ryerson, Renata Sawtell, Paul Hernandez, Aline Hagerimana, Pierre Laurin, Eric Turcotte, Shane Shapera, Hélène Manganas, André M. Cantin

Publikováno v: The European Respiratory Journal

PBI-4050 is a novel orally active small-molecule compound with demonstrated anti-fibrotic activity in several models of fibrosis, including lung fibrosis. We present results from our first clinical study of PBI-4050 in patients with idiopathic pulmon

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::410340e43330324b8fe13d84beff9849
http://europepmc.org/articles/PMC6422836

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání